Introduction
The ideal radiopharmaceutical is generally not metabolized and does not undergo a structural change in vivo. Radiopharmaceuticals can be used for both tissue accumulation studies and/or for tissue metabolic studies. For the former study, the ideal radiopharmaceutical is generally not metabolized and does not undergo a structural change in vivo. For the latter study, the ideal radiopharmaceutical is only metabolized after its accumulation in the target tissue. An important feature of nuclear medicine images is that these images reflect biological functions. Radiopharmaceuticals that are administered to the body provide information regarding the biological functions that are involved in their accumulation, which vary according to the chemical structure of the radiopharmaceutical. If the structure of the radiopharmaceutical changes before it goes into the tissues, then the behavior of this modified radiopharmaceutical will differ from that of the administered parental radiopharmaceutical. Thus, nuclear medicine images obtained with such a radiopharmaceutical would not accurately reflect biological function. However, some radiopharmaceuticals are known to be metabolized in vivo and such radiopharmaceuticals can provide important biological 5 ArticleIMP data [1] . In particular, 123 I-N-isopropyl-p-iodoamphetamine ( 123 I-IMP) is metabolized in stages and converted to 123 I-p-iodoamphetamine ( 123 I-PIA) [2] .
Currently, 123 I-IMP is widely used in clinical practice to examine regional cerebral blood flow (rCBF) [3, 4] . The input function of 123 I-IMP is calculated based on octanol-water partition coefficients because the lipophilic nature of the 123 I-IMP metabolites gradually decrease as 123 I-IMP is metabolized. However, 123 I-IMP can potentially provide not only rCBF data but also data regarding another important diagnostic parameter; CYP activity. Our research group has identified CYP2C19 as the enzyme that metabolizes N-isopropyl-p-iodoamphetamine (cold-IMP) and has shown using high-performance liquid chromatography (HPLC) that CYP2C19 converts cold-IMP to p-iodoamphetamine (cold-PIA) in pooled microsomes from human liver (HLM) [5] .
CYP2C19 is one of the cytochrome P450 enzymes that are involved in the metabolism of medicines [6] . However, four phenotypes of the CYP2C19 gene are expressed; extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM), and ultra-rapid metabolizer (UM) [7] . In general, a PM has little In the present study, we aimed to detect variations in CYP activity in a living organism by performing metabolic experiments in mice. These data can be used as a basic study of 123 I-IMP metabolite analysis for individualized medicine.
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Materials and Methods
Materials
Reagent-grade chemicals (e.g. potassium dihydrogenphosphate, dipotassium hydorogenphosphate, disodium edetate dihydrate, 60% perchloric acid, p-chlorobenzoic acid, and acetonitrile) were purchased from Nacalai Tesque (Kyoto, Japan). Β-NADP + and glucose-6-phosphate dehydrogenase were obtained from Oriental Yeast (Osaka, Japan). SKF-525A was obtained from Enzo Life Science (Zandhoven, Belgium).
125 I-IMP and 123 I-IMP were provided free by Nihon Medi-Physics (Chiba, Japan).
Preparation of pooled homogenates of mouse liver (MLH)
Animal studies were approved by the Animal Care Committee at Kanazawa University and were conducted in accordance with international standards for animal welfare and institutional guidelines.
Six male mice (ddY, 6 weeks old, Japan SLC, Tokyo, Japan) were euthanized with anesthesia using diethyl ether. The liver was then removed and weighed. After addition of Krebs-Ringer phosphate buffer (KRPB, pH 7.4) to the livers, the mixture 8 ArticleIMP was homogenized using an ultrasonic homogenizer. The protein content was quantified using the bicinchoninic acid method [8] . The mixture was incubated at 37 °C for 20 min. The reaction was stopped by adding perchloric acid, following which 20 μM p-chlorobenzoic acid was added as the internal standard. Subsequently, these samples were centrifuged for 5 min at 18000 g, and 100 μL supernatant was analyzed using HPLC.
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Biodistribution studies of 125 I-IMP in mice
These studies were performed to evaluate the effects of SKF-525A on the 
Metabolism of 123 I-IMP and its inhibition by SKF-525A in mice
Mice were pretreated with or without SKF-525A (1.25 μM, 100 μL) in saline solution, and, 3 min later, 123 I-IMP (7.4 MBq, 100 μL) was administered via the tail vein. Fifteen minutes after 123 I-IMP injection, mice were sacrificed by cervical dislocation under deep ether anesthesia. Blood was collected and deproteinized by adding 50 μL perchloric acid. Subsequently, the mixture was centrifuged for 5 min at 18000 g, and 100 μL supernatant was analyzed using HPLC. The liver and kidney were excised and weighed. After addition of KRPB to the liver and kidney, the 11 ArticleIMP mixture was homogenized using an ultrasonic homogenizer. The homogenates were deproteinized by adding perchloric acid, centrifuged for 5 min at 18000 g, and 100 μL supernatant was analyzed using HPLC. Ratio of the peak area of 125 I-or 123 I-PIA to the total area of significant peaks.
HPLC analysis of
Selection of radioactive isotope (RI)
125 I-IMP was used instead of 123 I-IMP for in vitro experiments and the biodistribution study because of its longer half-life. However, to detect radioactivity in the in vivo CYP activity assay using the HPLC system, it was necessary to have high levels of radioactivity in the homogenates of the excised organs. Unfortunately, the concentration of 125 I-IMP in the homogenates was too low for detection by this assay.
Since the volume of 125 I-IMP solution that would contain the required radioactivity was too large to administer to mice, we therefore used 123 I-IMP for the in vivo CYP activity assay experiment.
Statistical analysis
All results represent the average of least three experiments and are expressed as the mean ± SD. Data were analyzed using Student's t-test, and P < 0.05 was considered statistically significant. Figure 1A . In contrast, only parental 125 I-IMP was detected in a reaction mixture in the absence of the NADPH-generating system (Fig. 1B) . The normalized peak area of 125 I-PIA increased depending on the incubation time and the MLH concentration ( Fig.   2 ). At each incubation time, the normalized peak area of 125 I-PIA was maximal at 1000 μg protein/sample, and was lower at 2000 μg protein/sample due to NADPH depletion.
In the metabolic inhibition experiment in vitro,
125
I-PIA production was reduced in a concentration-dependent manner following addition of the selective CYP inhibitor SKF-525A (Fig. 3) . Figure 4 shows the in vivo data for blood, liver and kidney from Table 1 in graph form and compares the effect of SKF-525A on accumulated radioactivity.
There was no significant difference in the radioactive blood levels (A), or in the accumulated radioactivity levels in the liver (B) between the groups with or without SKF-525A. However, in the kidney (C), the accumulated level of 125 I-IMP plus 125 I-PIA at 5 min was higher in the SKF-525A group than in the control group (p < 0.05). These results indicate slightly faster distribution of 125 I-IMP plus 125 I-PIA to the kidney following co-administration of SKF-525A.
In HPLC analysis of the blood of mice administered 123 I-IMP, peaks of parental 123 I-IMP and the metabolite 123 I-PIA were detected in both the control and the SKF-525A groups. However, the normalized peak area of 123 I-PIA was markedly and significantly reduced compared with the control group due to the SKF-525A loading.
Moreover, whereas peaks of both 123 I-IMP and 123 I-PIA were detected in organ homogenates prepared from control mice, only a peak of parental 123 I-IMP was detected in organ homogenates prepared from mice loaded with SKF-525A ( Table 2 ).
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Discussion
Considerable individual differences exist in the pharmacokinetics of humans.
In most cases, the differences result from individual differences in the activity of drug-metabolizing enzymes as typified by CYP. Genetic polymorphisms are cited as the main factors responsible for individual differences in the activity of drug-metabolizing enzymes [11, 12] . Individuals with very low or very high metabolic capacities exist due to genetic polymorphisms in CYP, and are described as PM and EM respectively [13, 14] . Currently, such individual differences at the genetic level are distinguished by genetic analysis. However, genetic analysis cannot determine individual metabolic capacity at a particular point of time, which involves a variety of factors such as concomitant ingestion of different medicines, alcohol intake and deterioration in liver function due to aging. On the other hand, our method based on metabolite analysis can measure an individual's metabolic capability that reflects all of the factors described above. As previously indicated, to date 123 I-IMP has only been used to examine rCBF. However, based on our data, 123 I-IMP will be able to provide diagnostic information regarding metabolic function. On a relevant note, it will also be possible to accurately calculate input function by measuring the amount of an 123 I-IMP metabolite because the ratio of lipophilic metabolites that contaminate the octanol fraction will change according to the CYP activity of the individual patient.
Thus, the present study provides an important basis for accurate assessment of input function and for establishment of an index that can be used to determine the dose of medicine to be prescribed for individuals. In brief, competition with 123 I-IMP can be used for dose determination of medicines that are non-radioactive and are substrates of CYP2C19, such as imipramine, clomipramine, omeprazole and cimetidine. These non-radioactive medicines inhibit metabolism of 123 I-IMP in a similar manner to SKF-525A.
In our previous study with HLM, cold-IMP was metabolized by CYP2C19 to cold-PIA [5] . However, IMP-metabolizing enzymes in mice have not been identified, and important species differences are present between humans and mice. In addition, the number of molecules of 125 I-or 123 I-IMP that are accumulated in HLM or in organs after in vivo administration is very low. For these reasons, it was necessary to detect 125 I-or 123 I-IMP, as well as cold-IMP, using an analytical method such as HPLC.
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ArticleIMP CYPs are drug-metabolizing enzymes that act when NADPH is present as an energy source [15] . In in vitro experiments, 125 I-IMP and 125 I-PIA were detected with high sensitivity using HPLC, and we confirmed that 125 I-IMP was metabolized and converted to 125 I-PIA only in the presence of NADPH. In addition, the normalized area of the 125 I-PIA peak increased in a manner that was dependent on the protein concentration of MLH and on the incubation time (Fig. 2) . We therefore concluded that the metabolism of ArticleIMP SKF-525A concentration-dependent manner (Fig. 3) . Based on these results, we inferred that 125 I-IMP was metabolized by CYP in mice as well as in humans.
In the biodistribution study, 125 I-PIA cannot be distinguished from 125 I-IMP, because they both contain the same radionuclide; 125 I. Therefore this study evaluated As shown in Table 2 , following preloading of SKF-525A, the peak of 123 I-PIA disappeared in the liver and kidney and the normalized peak area of 123 I-PIA was significantly reduced in the blood. We considered that these decreases in 123 I-PIA levels were caused by decreased CYP activity, and not by administration of SKF-525A because the radioactivity in other organs was not significantly altered (Table 1 and Fig.   4 ).
In general, careful consideration is necessary in discussion of the metabolism of medicines administered at different concentrations, because it is known that the velocity of metabolic enzymatic reactions depends on the concentration of the substrate, and, furthermore, that metabolic enzymes other than the CYP family are present. However, when the focus is on one enzyme and its labeled substrate, it is possible to discuss the metabolism of the labeled substrate that is administered at tracer concentrations based on the premise that the species and function of the enzymes that metabolize this substrate do not change in the presence of a tracer concentration of the substrate. An example of such a study is the microdose study reported by Tozuka et al [16] . Although the present experiments were performed using mice, we consider that the metabolic rate of 123 I-IMP will similarly fluctuate depending on CYP activity in humans.
In humans, a medicine that is a substrate for CYP2C19 would behave as a CYP2C19 inhibitor instead of SKF-525A. Subsequent 123 I-IMP metabolite analysis would then indicate variation in CYP2C19 activity due to ingestion of the medicine.
In addition, the only radiopharmaceutical that can currently be used for CYP activity-measurement methods that are based on metabolic changes is 123 I-IMP. This is because radiopharmaceuticals used in this method must meet the following conditions: a metabolizing enzyme must have been identified, its metabolites must also be radioactive, and detection and separation from the parental substance must be easy. 
